Cart
sales@molnova.com
Navitoclax-piperazine
CAS No. 2143096-93-7
Navitoclax-piperazine( ABT-263-piperazine )
Catalog No. M23975 CAS No. 2143096-93-7
Navitoclax-piperazine is an inhibitor of B-cell lymphoma extra large (BCL-XL).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 292 | In Stock |
|
| 10MG | 495 | In Stock |
|
| 25MG | 781 | In Stock |
|
| 50MG | 1071 | In Stock |
|
| 100MG | 1449 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNavitoclax-piperazine
-
NoteResearch use only, not for human use.
-
Brief DescriptionNavitoclax-piperazine is an inhibitor of B-cell lymphoma extra large (BCL-XL).
-
DescriptionNavitoclax-piperazine is an inhibitor of B-cell lymphoma extra large (BCL-XL).
-
In Vitro——
-
In Vivo——
-
SynonymsABT-263-piperazine
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-xL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2143096-93-7
-
Formula Weight973.63
-
Molecular FormulaC47H56ClF3N6O5S3
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL?(256.77 mM;?Need ultrasonic)
-
SMILESCC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCNCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019).
molnova catalog
related products
-
BM-1197
BM-1197 is a potent, specific dual inhibitor of Bcl-2 and Bcl-xL with Ki of <1 nM.
-
BCL6-IN-3
BCL6-IN-3 is a potent BCL6 inhibitor with GI50 of 70 nM in SU-DHL4 cells. BCL6-in-3 regulates cell activation, differentiation, DNA damage and apoptosis, and has antitumor activity.
-
BCL6-IN-6
BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.
